Technology
Products
Market
About us
News
- Regulatory news
Investor relations

RP101 Phase II clinical results

2020-03-11

Redwood Pharma

We develop ophthalmic drugs that address major medical needs. We focus on early-stage clinical development. Our long-term strategy is to enter into licence agreements with other drug companies who will in turn introduce products for the global market.

Welcome
Technology
Products
Market
About us
News
- Regulatory news
Investor relations
- Reports
- Presentations
Privacy Policy

Contact

Martin Vidaeus – CEO
070-232 29 29
martin.vidaeus@redwoodpharma.com

Ringvägen 100E, floor 9
118 60 Stockholm, Sweden